Insider Transactions in Q1 2022 at Amylyx Pharmaceuticals, Inc. (AMLX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2022
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+50.0%
|
-
|
|
Jan 11
2022
|
Invest 1 B.V. Als > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,955,889
+47.38%
|
-
|
|
Jan 11
2022
|
Morningside Venture Investments LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
263,158
+2.41%
|
$5,000,002
$19.0 P/Share
|
|
Jan 11
2022
|
Morningside Venture Investments LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
10,415,650
+50.0%
|
-
|
|
Jan 11
2022
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
2,300,000
+50.0%
|
$43,700,000
$19.0 P/Share
|
|
Jan 11
2022
|
Viking Global Investors LP |
BUY
Conversion of derivative security
|
Indirect |
4,870,536
+50.0%
|
-
|
|
Jan 06
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+2.84%
|
-
|
|
Jan 06
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,870
+0.2%
|
-
|
|
Jan 06
2022
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,667
+50.0%
|
-
|
|
Jan 06
2022
|
Margaret Olinger Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
6,842
+3.06%
|
$129,998
$19.0 P/Share
|
|
Jan 06
2022
|
Margaret Olinger Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,333
+11.89%
|
-
|
|
Jan 06
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+2.84%
|
-
|
|
Jan 06
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,870
+0.2%
|
-
|
|
Jan 06
2022
|
George M Milne Jr |
BUY
Open market or private purchase
|
Direct |
26,315
+10.62%
|
$499,985
$19.0 P/Share
|
|
Jan 06
2022
|
Patrick D Yeramian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,333
+12.07%
|
-
|
|
Jan 06
2022
|
Isaac Cheng Director |
BUY
Open market or private purchase
|
Direct |
6,578
+50.0%
|
$124,982
$19.0 P/Share
|
|
Jan 06
2022
|
Isaac Cheng Director |
BUY
Conversion of derivative security
|
Indirect |
10,415,650
+29.62%
|
-
|
|
Jan 06
2022
|
Paul R. Fonteyne |
BUY
Open market or private purchase
|
Direct |
3,947
+50.0%
|
$74,993
$19.0 P/Share
|